cobas HPV
Roche Molecular Systems, Inc. · Decision date Oct 27, 2026
What did the FDA decide?
FDA posted a 30-day notice for PMA supplement P190028/S026 from Roche Molecular Systems, Inc. The decision record, dated 2026-10-27, lists the supplement reason as a process change involving manufacturer, sterilizer, packager, or supplier, and the statement says the purpose is to change the manufacturing process for oligonucleotides. The device is identified as a kit for DNA detection of human papillomavirus under product code MAQ.
The posted record does not include the attached FDA summary or other documents, so the specific oligonucleotide change, affected manufacturing site, and any labeling or performance details are absent. This supplement is not a new approval of the whole system and does not by itself establish safety or clinical effectiveness. The relationship to the original PMA is limited to the identifier P190028.
FDA approval order statement
to change the manufacturing process for oligonucleotides
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Microbiology
- Decision date
- Oct 27, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P190028/S026
- Regulatory pathway
- PMA supplement
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- MAQ
- Decision code
- OK30
- Decision date
- Oct 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- MAQ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P190028. Subsequent supplements may change the device or its indications.
FDA decision timeline
P190028 · Original PMA
cobas HPV for use on the cobas 6800/8800 Systems
P190028/S026 received
Application receipt date recorded by FDA.
P190028/S026 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P190028. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190028
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Roche Molecular Systems, Inc. | PMA approval | Apr 3, 2020 | FDA |
Explore the linked device profile
Other records with product code MAQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cobas HPVP100020/S066 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Alinity m HR HPVP230003/S019 | Abbott Molecular, Inc. | PMA supplement | Sep 2, 2026 | FDA |
Alinity m HR HPVP230003 | Abbott Molecular, Inc. | PMA approval | Nov 1, 2023 | FDA |
COBAS HPV TESTP100020 | Roche Molecular Systems, Inc. | PMA approval | Apr 19, 2011 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Molecular Systems, Inc.
- Headquarters
- Not reported
- Brand website
- roche.com
- FDA applicant address
- 4300 Hacienda Dr., Pleasanton, CA, 94588
Sources and methodology
- Original FDA record: P190028/S026
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



